In this issue, the revised version of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders are published (Bandelow et al. 2002) . Although only 7 years have passed since the first publication of the guidelines, the Task Force now saw a need for a revised version, as new treatments have emerged and evidence for existing treatments has been consolidated. Also, all other guidelines of the WFSBP (Bauer et al. 2002a (Bauer et al. ,b, 2007 Falkai et al. 2005 Falkai et al. , 2006 Grunze et al. 2002 Grunze et al. , 2003 Grunze et al. , 2004 Herpertz et al. 2007; Soyka et al. 2008 ) will be updated in future.
The present guideline is now based on over 500 evaluable controlled studies, and many more studies had to be evaluated for possible inclusion.
Clinicians are bombarded with ''evidence'' that a new treatment is more effective, has fewer side effects, faster onset of action or has other advantages. With an increasing number of treatment options available for patients with psychiatric disorders over the last decade and the growing body of evidence describing their efficacy and safety, clinicians often find it difficult to determine the best appropriate treatment for each patient. One aim of guidelines is to summarize and to simplify such findings, by carefully weighing advantages and disadvantages of the available treatment interventions. The main results are typically condensed into evidence categories, which are based on efficacy. However, not only efficacy is important for decision finding. For instance, of two treatments with the same efficacy, the one with the most benign side effect profile or the lowest costs should be recommended. The results of the guideline consensus process can be finally summarized in recommendation levels, which also take the riskÁbenefit ratio of the therapeutic interventions into account.
The various types of evidence can be arranged hierarchically in a grading system according to strength, with randomized controlled trials at the most definitive end and case reports or opinions of ''respected authorities'', which are not based on any published evidence (''eminence-based medicine''), at the least definitive end of the spectrum. When searching for a commonly used grading system of categories of evidence for the guidelines of the WFSBP, we found that there is no generally accepted system for medicinal or psychological treatment interventions. It would be desirable that the same hierarchy of evidence is used in all such guidelines. However, over 100 different systems exist for grading evidence, and none of these is preferred by most guideline panels. The reason for this diversity probably lies in the different requirements in different specialties in medicine. It may be difficult to construct a system that applies to all fields of medicine. In psychiatry, we are interested in whether a drug is better than placebo for treating depression or whether it can prevent relapses in bipolar disorder, whereas in surgery we are interested in whether a certain operation can prevent death from a rare cancer type; in internal medicine we may search for an optimal strategy to lower cholesterol levels to reduce the risk of cardiovascular disease. In all these different issues, different study types are necessary, and it is not easy to develop an evidence grading system for all these study types. There are efforts ongoing to find a general system for rating quality of evidence (Guyatt et al. 2008) . However, for the WFSBP guidelines, we did not find a grading system that was adequate for the typical data in psychopharmacology. On the contrary, we found a number of problems with the existing systems, with the consequence that interventions with weak efficacy could be upgraded to the first level of evidence under certain circumstances.
For example, we found it difficult to adopt the system by Eccles and Mason (2001) which was used in the recent guidelines for panic disorder and generalized anxiety disorder of the U.K. National Institute for Clinical Excellence (NICE) (NICE 2007) , due to some methodological issues. In Table I , this system is compared with the grading scheme of the WFSBP guidelines. is also problematic. Meta-analyses have some advantages. They may sometimes permit conclusions about efficacy to be drawn with a greater degree of confidence than is possible with qualitative reviews. When direct comparisons of two treatments are lacking, these can be compared by using meta-analysis, even when different rating scales have been used in these trials. When conflicting results exist for a certain treatment, meta-analysis can solve these discrepancies. While a single study is only powered for analysing the whole study population, a metaanalysis of many studies may have the statistical power to analyse smaller subgroups within the population (e.g., elderly patients). However, meta-analyses have a number of methodological shortcomings, which make them less reliable than the original studies: Á Effect sizes are not easily comparable across different studies, when different efficacy measures are used. Even within a study, effect sizes may differ substantially, e.g., when comparing the results of the Hamilton Anxiety Scale with the Clinical Global Impression Scale for the same patients. Á By combining many small studies to a large data set, the statistical power may increase to a sufficient magnitude to yield statistically significant results, but these effect sizes may be so small that they are meaningless for the patients. According to the Eccles & Mason system, a drug that was not superior to placebo in three wellpowered studies could nevertheless reach Level 1 evidence after these studies were pooled in a meta-analysis, because of the artificially inflated power in the larger sample size. Á In a meta-analysis, studies are included that differ substantially in patient selection, average illness severity, intervention, dosage, study duration, and outcome parameters. This may also be seen as an advantage, as the findings attain higher external validity. In real life, a new drug should work in all patients and not only in selected subgroups. However, generalizability of meta-analyses may also be a In a clinical trial at a university department of psychology, cognitive behavioural therapy (CBT) for panic disorder is compared with a wait list control. Participants having the luck to be selected randomly for CBT have a high positive expectancy that the treatment will improve their symptoms, because they are not blind to the treatment condition, CBT has a good reputation, and the therapists of the centre are well-known specialists in their field. Additionally, they are allowed to be kept on their previous medications, e.g., SSRIs and benzodiazepines, according to typical study protocols used in this kind of design. In a second study, panic patients take part in a double-blind trial with a new drug designed for licensing the drug. The participants have the expectancy that placebo is not effective and there is also a possibility that the new drug will not be effective. Both studies are methodologically sound. However, a meta-analysis comparing the effect sizes of both studies would be biased, as the effect sizes of the first study are inflated due to positive expectancy and additional drug effects, while expectancy in the second study is lowered. Á Meta-analyses are often contemptuously described as ''garbage-in/garbage-out'', meaning that excellent and flawed studies are mixed together in one analysis. Therefore, studies should only be selected when they fulfil certain methodological standards, regarding sample size, randomization, control group, dosage, rating scales, statistical methods, etc. However, by varying these methodological requirements, study selection may be biased, by including favoured studies and excluding other studies on the basis of putative flaws. This ''cherry-picking'' may be one of the most important reasons why meta-analyses of the same database often come to contradictory results. For example, different meta-analyses comparing CBT and drug therapy for panic disorder found either superiority of CBT over drug therapy or equal efficacy. Some found no gains from the combination of both, while others found a substantial advantage (Bandelow et al. 2007 ). Á The statistical power to detect differences between treatments is dependent on both the number of observations and the magnitude of the effect. This also applies to meta-analyses. In the case of conventional meta-analysis, N is the number of studies included. Thus the power of a metaanalysis of only two or three studies is limited, unless the effect sizes are large, which is unlikely in the case of studies in should be commented upon that are widely used in care primary, but were either shown to be ineffective in RCTs or were never investigated in this disorder. Absence of evidence is not the same as evidence of absence of an effect. For example, there is strong negative evidence against the use of beta-blockers in anxiety disorders, because all available studies showed non-superiority to placebo. However, when there is lack of evidence for one drug in a special indication, it could still be tried in desperate cases of patients unresponsive to standard treatments, while such an attempt should not be undertaken with a drug that definitely showed negative evidence.
Because of these shortcomings of existing grading systems, we decided to develop special levels of evidence for the WFSBP guidelines, by integrating suggestions from other guidelines and by trying to use definitions that are optimally adapted to the situation of evidential data in psychiatry, in order to provide optimal transparency for the users of this guideline. It is planned to use this grading system for categories of evidence for all future revisions of the guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP). Consensus guidelines may improve the overall quality of treatment (however, adherence to pub-lished guidelines is not always satisfactory). Guidelines also may have some influence on the design of future studies. By insisting on high quality standards, they can stimulate the application of rigorous methodological standards.
